Leo Pharma boss on newly purchased drug: "It is a very cleverly designed antibody"

Kim Kjøller, research director at Leo Pharma, wants to attack atopic dermatitus from all sides, and the company's new DKK 3.9 billion (USD 569 million) purchase is an addition to that plan.

Kim Kjøller, research director at Leo Pharma. | Photo: Leo Pharma/ PR

On Wednesday, Leo Pharma added another potential weapon to its arsenal of treatments for skin disease atopic dermatitis (eczema), when the company paid DKK 270 million (USD 39 million) and promised DKK 3.6 billion (USD 526 billion) in milestone payments for antibody FB825.

Kim Kjøller, research director at Leo Pharma, is very happy with the deal.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs